Last reviewed · How we verify
Crinone8
Crinone is a progesterone vaginal gel that delivers micronized progesterone directly to the reproductive tract to support luteal phase function and early pregnancy.
Crinone is a progesterone vaginal gel that delivers micronized progesterone directly to the reproductive tract to support luteal phase function and early pregnancy. Used for Luteal phase support in assisted reproductive technology (ART) cycles, Progesterone replacement therapy in women with progesterone deficiency.
At a glance
| Generic name | Crinone8 |
|---|---|
| Also known as | vaginal progesterone |
| Sponsor | University Magna Graecia |
| Drug class | Progesterone replacement therapy |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Fertility |
| Phase | Phase 3 |
Mechanism of action
Crinone provides sustained-release progesterone via a bioadhesive vaginal gel formulation, allowing local delivery to the endometrium and systemic absorption. This supports endometrial proliferation and secretion necessary for embryo implantation and early pregnancy maintenance, particularly in assisted reproductive technology (ART) cycles and luteal phase support.
Approved indications
- Luteal phase support in assisted reproductive technology (ART) cycles
- Progesterone replacement therapy in women with progesterone deficiency
Common side effects
- Vaginal discharge or irritation
- Headache
- Breast tenderness
- Abdominal pain or cramping
Key clinical trials
- Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer. (PHASE3)
- PErsonalized Addition of Recombinant LH in Ovarian Stimulation (PHASE4)
- Efficacy and Safety of Crinone Versus Combination Medication (ACCESS) (PHASE4)
- Randomized Trial of Maternal Progesterone Therapy (PHASE2)
- Sexual Absorption of Vaginal Progesterone (PHASE4)
- An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029) (PHASE3)
- Luteal Support in Frozen-Thawed Embryo Transfer Cycles (PHASE4)
- Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |